HRMY Q3 EPS Miss on Costs, Wakix Growth Intact

What happened

Harmony Biosciences reported Q3 2025 results with EPS below consensus due to higher operating costs, particularly R&D and SG&A, while Wakix net revenue continued to grow at a robust rate. The company's quarter was consistent with the DeepValue master report's expectation of rising pipeline investment pressuring near-term margins, even as core commercial traction remains strong. Specifically, Wakix revenue grew approximately 29% year-over-year in Q3, with patient adds continuing, and management reiterated its 2026 revenue outlook supported by pipeline progress. The earnings miss was not a surprise given the multiple consecutive quarters of EPS underperformance highlighted in prior analysis, and the market's reaction reflects growing sensitivity to profitability rather than concerns about demand. Overall, the results confirm that the company is investing heavily in its pipeline (pitolisant HD, GR, PWS, EPX-100, etc.) which is eroding near-term earnings but is necessary to sustain long-term growth.

Implication

In the short term, the stock may continue to face pressure as investors scrutinize cost growth relative to revenue, but the underlying Wakix franchise remains on a high-teens growth trajectory with over 80% payer coverage and low market penetration. Over the next 6-18 months, the key monitorables are whether revenue growth remains above mid-teens and whether net margins stabilize in the low-20s as guided; current consensus already embeds some margin compression, so upside exists if execution is better than feared. The master report's valuation of ~$42 fair value suggests upside from current ~$36, with a trim level at $50, so the risk/reward remains favorable for a patient investor. However, investors must accept that near-term EPS will be noisy due to R&D spending, and any further pipeline setbacks could delay margin recovery and pressure the stock. Overall, the Q3 report does not alter the thesis materially; it validates both the growth and the cost pressure, and the stock remains a potential buy for those with a 6-12 month horizon.

Thesis delta

The thesis remains unchanged: HRMY is a high-margin narcolepsy franchise with durable Wakix growth, temporarily compressed by pipeline investment. The Q3 miss is consistent with expected margin pressure and does not signal deteriorating demand or competitive threats. The confirmation of 2026 revenue outlook and pipeline progress marginally reinforces the long-term growth optionality while near-term earnings volatility is already accounted for.